Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Finished Goods (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Finished Goods data on record, last reported at $991000.0 in Q2 2025.

  • For Q2 2025, Finished Goods rose 13.65% year-over-year to $991000.0; the TTM value through Jun 2025 reached $991000.0, up 13.65%, while the annual FY2024 figure was $717000.0, 523.48% up from the prior year.
  • Finished Goods reached $991000.0 in Q2 2025 per VRCA's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $1.2 million in Q1 2025 and bottomed at $115000.0 in Q4 2023.
  • Average Finished Goods over 3 years is $674875.0, with a median of $699000.0 recorded in 2024.
  • Peak YoY movement for Finished Goods: skyrocketed 523.48% in 2024, then increased 13.65% in 2025.
  • A 3-year view of Finished Goods shows it stood at $115000.0 in 2023, then surged by 523.48% to $717000.0 in 2024, then surged by 38.21% to $991000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $991000.0 in Q2 2025, $1.2 million in Q1 2025, and $717000.0 in Q4 2024.